Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]

• Nancy E. Hernandez,
• Wojciech Jankowski,
• Rahel Frick,
• Simon P. Kelow,
• Joseph H. Lubin,
• Vijaya Simhadri,
• Jared Adolf-Bryfogle,
• Sagar D. Khare,
• Roland L. Dunbrack, Jr.,
• Jeffrey J. Gray,
• Zuben E. Sauna

Affiliations

Nancy E. Hernandez

Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research U.S. FDA, Silver Spring, MD, USA

Wojciech Jankowski

Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research U.S. FDA, Silver Spring, MD, USA

Rahel Frick

Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA

Simon P. Kelow

Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA; Dept. of Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, PA, USA

Joseph H. Lubin

Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, USA

Vijaya Simhadri

Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research U.S. FDA, Silver Spring, MD, USA

Jared Adolf-Bryfogle

The Institute for Protein Innovation, Boston, MA, USA

Sagar D. Khare

Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, USA; Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ, USA

Roland L. Dunbrack, Jr.

Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA

Jeffrey J. Gray

Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA

Zuben E. Sauna

Hemostasis Branch 1, Division of Hemostasis, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research U.S. FDA, Silver Spring, MD, USA; Corresponding author.